Literature DB >> 29319430

Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities.

Shanna L Burke1, Tianyan Hu2, Nicole M Fava1, Tan Li3, Miriam J Rodriguez4, Katie L Schuldiner5, Aaron Burgess5, Angela Laird6.   

Abstract

This study examined biological sex differences in the development of mild cognitive impairment (MCI) and probable Alzheimer's disease (AD) development as predicted by changes in the hippocampus or white matter hyperintensities. A secondary data analysis of the National Alzheimer's Coordinating Center Uniform Data Set was conducted. We selected samples of participants with normal cognition at baseline who progressed to MCI (n = 483) and those who progressed to probable AD (n = 211) to determine if hippocampal volume or white matter hyperintensities (WMH) at baseline predicted progression to probable AD or MCI and whether the rate of progression differed between men and women. The survival analyses indicated that changes in hippocampal volumes affected the progression to probable AD (HR = 0.535, 95% CI [0.300-0.953]) only among women. White men had an increased rate of progression to AD (HR = 4.396, CI [1.012-19.08]; HR = 4.665, 95% CI [1.072-20.29]) compared to men in other race and ethnic groups. Among women, increases in hippocampal volume ratio led to decreased rates of progressing to MCI (HR = 0.386, 95% CI [0.166-0.901]). Increased WMH among men led to faster progression to MCI (HR = 1.048. 95% CI [1.011-1.086]). Women and men who were older at baseline were more likely to progress to MCI. In addition, results from longitudinal analyses showed that women with a higher CDR global score, older age at baseline, or more disinhibition symptoms experienced higher odds of MCI development. Changes in hippocampal volumes affect the progression to or odds of probable AD (and MCI) more so among women than men, while changes in WMH affected the progression to MCI only among men.

Entities:  

Keywords:  Alzheimer disease; brain; disease progression; hippocampus; magnetic resonance imaging; men; sex characteristics; white matter hyperintensities; women

Mesh:

Year:  2018        PMID: 29319430      PMCID: PMC6039284          DOI: 10.1080/08952841.2018.1419476

Source DB:  PubMed          Journal:  J Women Aging        ISSN: 0895-2841


  74 in total

1.  MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia.

Authors:  R Barber; C Ballard; I G McKeith; A Gholkar; J T O'Brien
Journal:  Neurology       Date:  2000-03-28       Impact factor: 9.910

2.  Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group.

Authors:  K Andersen; L J Launer; M E Dewey; L Letenneur; A Ott; J R Copeland; J F Dartigues; P Kragh-Sorensen; M Baldereschi; C Brayne; A Lobo; J M Martinez-Lage; T Stijnen; A Hofman
Journal:  Neurology       Date:  1999-12-10       Impact factor: 9.910

3.  Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction.

Authors:  K Yaffe; M Haan; A Byers; C Tangen; L Kuller
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

4.  Is the risk of developing Alzheimer's disease greater for women than for men?

Authors:  L E Hebert; P A Scherr; J J McCann; L A Beckett; D A Evans
Journal:  Am J Epidemiol       Date:  2001-01-15       Impact factor: 4.897

5.  Equivalent disruption of regional white matter microstructure in ageing healthy men and women.

Authors:  E V Sullivan; E Adalsteinsson; M Hedehus; C Ju; M Moseley; K O Lim; A Pfefferbaum
Journal:  Neuroreport       Date:  2001-01-22       Impact factor: 1.837

6.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.

Authors:  C R Jack; R C Petersen; Y Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  2000-08-22       Impact factor: 9.910

7.  Adverse childhood experiences and smoking during adolescence and adulthood.

Authors:  R F Anda; J B Croft; V J Felitti; D Nordenberg; W H Giles; D F Williamson; G A Giovino
Journal:  JAMA       Date:  1999-11-03       Impact factor: 56.272

8.  Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease.

Authors:  G Fein; V Di Sclafani; J Tanabe; V Cardenas; M W Weiner; W J Jagust; B R Reed; D Norman; N Schuff; L Kusdra; T Greenfield; H Chui
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

Review 9.  Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders.

Authors:  R M Sapolsky
Journal:  Arch Gen Psychiatry       Date:  2000-10

10.  Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population.

Authors:  A G Yip; C Brayne; D Easton; D C Rubinsztein
Journal:  J Med Genet       Date:  2002-09       Impact factor: 6.318

View more
  20 in total

1.  Sex Differences in Cognitive Changes in De Novo Parkinson's Disease.

Authors:  Ece Bayram; Sarah J Banks; Guogen Shan; Nikki Kaplan; Jessica Z K Caldwell
Journal:  J Int Neuropsychol Soc       Date:  2019-12-11       Impact factor: 2.892

Review 2.  Alzheimer's pathogenic mechanisms and underlying sex difference.

Authors:  Donghui Zhu; Axel Montagne; Zhen Zhao
Journal:  Cell Mol Life Sci       Date:  2021-04-12       Impact factor: 9.261

Review 3.  Sex is a defining feature of neuroimaging phenotypes in major brain disorders.

Authors:  Lauren E Salminen; Meral A Tubi; Joanna Bright; Sophia I Thomopoulos; Alyssa Wieand; Paul M Thompson
Journal:  Hum Brain Mapp       Date:  2021-05-05       Impact factor: 5.038

4.  Sex Differences in the White Matter and Myelinated Fibers of APP/PS1 Mice and the Effects of Running Exercise on the Sex Differences of AD Mice.

Authors:  Chun-Ni Zhou; Feng-Lei Chao; Yi Zhang; Lin Jiang; Lei Zhang; Yan-Min Luo; Qian Xiao; Lin-Mu Chen; Yong Tang
Journal:  Front Aging Neurosci       Date:  2018-08-17       Impact factor: 5.750

5.  White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.

Authors:  Anja Soldan; Corinne Pettigrew; Yuxin Zhu; Mei-Cheng Wang; Abhay Moghekar; Rebecca F Gottesman; Baljeet Singh; Oliver Martinez; Evan Fletcher; Charles DeCarli; Marilyn Albert
Journal:  Neurology       Date:  2019-12-30       Impact factor: 9.910

6.  Network Modeling Sex Differences in Brain Integrity and Metabolic Health.

Authors:  Janelle T Foret; Maria Dekhtyar; James H Cole; Drew D Gourley; Marie Caillaud; Hirofumi Tanaka; Andreana P Haley
Journal:  Front Aging Neurosci       Date:  2021-06-29       Impact factor: 5.750

7.  Pre-stroke cognitive impairment is associated with vascular imaging pathology: a prospective observational study.

Authors:  Till Schellhorn; Manuela Zucknick; Torunn Askim; Ragnhild Munthe-Kaas; Hege Ihle-Hansen; Yngve M Seljeseth; Anne-Brita Knapskog; Halvor Næss; Hanne Ellekjær; Pernille Thingstad; Torgeir Bruun Wyller; Ingvild Saltvedt; Mona K Beyer
Journal:  BMC Geriatr       Date:  2021-06-14       Impact factor: 3.921

8.  The Association Between Functional Assessment and Structural Brain Biomarkers in an Ethnically Diverse Sample With Normal Cognition, Mild Cognitive Impairment, or Dementia.

Authors:  Fernanda Arruda; Mónica Rosselli; Maria T Greig; David A Loewenstein; Merike Lang; Valeria L Torres; Idaly Vélez-Uribe; Joshua Conniff; Warren W Barker; Rosie E Curiel; Malek Adjouadi; Ranjan Duara
Journal:  Arch Clin Neuropsychol       Date:  2021-01-15       Impact factor: 3.448

9.  Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume.

Authors:  Jessica Z K Caldwell; Jody-Lynn Berg; Guogen Shan; Jeffrey L Cummings; Sarah J Banks
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  Cognitive reserve and midlife vascular risk: Cognitive and clinical outcomes.

Authors:  Anja Soldan; Corinne Pettigrew; Yuxin Zhu; Mei-Cheng Wang; Rebecca F Gottesman; Charles DeCarli; Marilyn Albert
Journal:  Ann Clin Transl Neurol       Date:  2020-07-21       Impact factor: 5.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.